Drugs that contain Fidaxomicin

1. Drug name - DIFICID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(9 months from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(4 years from now)

CN102746353A CUBIST PHARMS LLC Macro-Cyclic Polymorphic Substance, Composition With This Macro-Cyclic Polymorphic Substance, Usage And Preparation Method Thereof
May, 2016

(6 years ago)

CN101340919B CUBIST PHARMS LLC Method Of Treating Clostridium Difficile Associated Diarrhea
Dec, 2017

(4 years ago)

CN101340919A CUBIST PHARMS LLC Method Of Treating Clostridium Difficile-Associated Diarrhea
Dec, 2017

(4 years ago)

CN100519757C CUBIST PHARMS LLC Preparation Of Tiacumicins
Jul, 2023

(9 months from now)

CN1688707A CUBIST PHARMS LLC Preparation Of Table Hook
Jul, 2023

(9 months from now)

CN102614207B CUBIST PHARMS LLC 18 Membered Macrocyclic Compounds And Analogues Thereof
Jan, 2025

(2 years from now)

CN102614207A CUBIST PHARMS LLC 18-Membered Macrocyclic Compound And Analog Thereof
Jan, 2025

(2 years from now)

CN101128114B CUBIST PHARMS LLC 18 Membered Macrocyclic Compounds And Analogues Thereof
Jan, 2025

(2 years from now)

CN101128114A CUBIST PHARMS LLC 18-Membered Macrocycles Compound And Analogs
Jan, 2025

(2 years from now)

CN101663312B CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof
Jan, 2028

(5 years from now)

CN101663312A CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof
Jan, 2028

(5 years from now)

EP2070530B1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP1765312A2 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP1765312A4 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2305245A1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP1765312B1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2070530A1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2305244A1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2305245B1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2305244B1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP1539977A2 CUBIST PHARMS LLC Tiacumicin Production
Dec, 2026

(4 years from now)

EP1539977A4 CUBIST PHARMS LLC Tiacumicin Production
Dec, 2026

(4 years from now)

EP1539977B1 CUBIST PHARMS LLC Tiacumicin Production
Dec, 2026

(4 years from now)

EP3412678A1 CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof
Jan, 2028

(5 years from now)

EP2125850A1 CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, Methods Of Manufacture And Use Thereof
Jan, 2028

(5 years from now)

EP2125850B1 CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, Methods Of Manufacture And Use Thereof
Jan, 2028

(5 years from now)

EP3412678B1 CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof
Jan, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Jan, 2024

(1 year, 3 months from now)

US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Mar, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jul, 2027

(4 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jul, 2027

(4 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Sep, 2027

(4 years from now)

US8859510

(Pediatric)

CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jan, 2028

(5 years from now)

US7378508

(Pediatric)

CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B Jan, 2028

(5 years from now)

US7863249

(Pediatric)

CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jan, 2028

(5 years from now)

US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds May, 2034

(11 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds Nov, 2034

(12 years from now)

Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.